Intelligence · Clinical Pipeline

Infectious disease R&D Pipeline

Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Programs: 1,126

Quick answer

Infectious disease: NovaPharmaNews indexes 1,126 infectious disease clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Top sponsors

telaprevir

Vertex Pharmaceuticals (Australia) Pty.

Chronic Hepatitis C Virus Infection

phase 2 small molecule terminated

1 trial
telaprevir or matching placebo

Vertex Pharmaceuticals (Australia) Pty.

Hepatitis C

phase 2 small molecule completed

1 trial
thalidomide

Ultragenyx UK Limited

HIV Infections

phase 2 small molecule completed

1 trial
zelicapavir

ENANTA PHARMACEUTICALS INC

RSV Infection

phase 2 small molecule active

1 trial
zinc supplementation

United Therapeutics Europe Ltd

HIV Infections

phase 2 small molecule completed

1 trial
(+)-SJ000557733

CNS Pharmaceuticals

Plasmodium Falciparum Malaria

phase 1 small molecule completed

1 trial
11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

Xiyuan Hospital of China Academy of Chinese Medical Sciences

HPV Infection

phase 1 mab completed

1 trial
480 mg Piperaquine phosphate

CNS Pharmaceuticals

Malaria

phase 1 small molecule completed

1 trial
9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

Lxo Ireland Designated Activity Company

HPV Infection

phase 1 mab active

1 trial
A First-in-Human, randomised, double blind, placebo-controlled, single ascending dose trial to evaluate safety, tolerability, and pharmacokinetics of APC148 in healthy adults.

Lacuna Pharma Pty Ltd

Urinary tract infections (UTIs)/complicated UTI (cUTI)

phase 1 other active

1 trial
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001

Wuhan Createrna Science and Technology Co., Ltd

Chronic Hepatitis B

phase 1 other active

1 trial
A Phase I study to evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects

Lacuna Pharma Pty Ltd

Severe infections caused by Gram-negative bacteria

phase 1 other active

1 trial
A Randomized, Blinded, Placebo-Controlled Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects with Chronic Hepatitis B Virus Infection

ASSEMBLY BIOSCIENCES, INC.

chronic hepatitis B virus infection (cHBV)

phase 1 other active

1 trial
A clinical study of MK-1289 in healthy adult men (MK-1289-001)

Merck Sharp and Dohme

COVID-19 Infection

phase 1 other active

1 trial
A clinical study of MK-3508 in healthy people (MK-3508-006)

Merck Sharp and Dohme

Respiratory syncytial virus infection

phase 1 other active

1 trial
A clinical study of MK-4646 in healthy people (MK-4646-002)

Merck Sharp and Dohme

HIV infection

phase 1 other active

1 trial
A clinical study of MK-4646 in people with HIV (MK-4646-003)

Merck Sharp and Dohme

HIV infection

phase 1 other active

1 trial
A clinical trial investigating the safety and biological activity of the antibody BNT351 in adults living without and with HIV

BioNTech SE

HIV-1 infection

phase 1 other active

1 trial
A first in human study of people with chronic hepatitis B, where all participants will receive the new drug PBGENE-HBV. This study will use increasing dose amounts of the drug to see how safe and bearable it is. The study will also test how well PBGENE-HBV works and how it is processed by the body.

Chongqing Precision Biotech Co., Ltd

Chronic Hepatitis B

phase 1 other active

1 trial
A first-in-human trial to evaluate safety, tolerability, and pharmacokinetics of single and multiple oral doses of Debio 1453P in healthy adults

Alphapharm Pty Ltd

Sexual Transmitted Infection (STI)

phase 1 other active

1 trial
A phase 1 study of FluBHPVE6E7 immunotherapy in patients with HPV16-associated oropharyngeal squamous cell carcinoma

Blue Earth Diagnostics Ireland Ltd

Treatment of human papilloma virus (HPV) associated infections and cancers

phase 1 other active

1 trial
A randomized, Phase I, single-center, observer-blind, active-controlled study to evaluate the safety, tolerability and immunogenicity of one single administration of PCV-LITE, a novel adjuvanted pneumococcal conjugate vaccine at one dose level of LiteVax Adjuvant, in healthy participants aged 18-50 years.

Teva Pharma GmbH

Pneumococcal infection

phase 1 other active

1 trial
A randomized, single-blind, placebo-controlled, study to examine the safety, tolerability, and pharmacokinetics of M6229 administered as a 120-hour continuous infusion at two dose levels versus placebo in healthy subjects

Lacuna Pharma Pty Ltd

Sepsis and Septic Shock

phase 1 other active

1 trial
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg / 5 mL of clavulanic acid powder for oral suspension in healthy volunteers under fed conditions.

Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

infection

phase 1 other active

1 trial
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Taromentin® 500 mg + 125 mg film-coated tablets versus Augmentin® 500 mg + 125 mg film-coated tablets in healthy volunteers under fed conditions.

Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

infections

phase 1 other active

1 trial
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on two amoxicillin-clavulanic acid film-coated tablet formulations in healthy volunteers under fed conditions.

Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

infections

phase 1 other active

1 trial
A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.

Novartis Pharmaceuticals

Malaria

phase 1 other active

1 trial
A study of different dose levels of FluBHPVE6E7 or placebo in women infected with the virus Human Papilloma Type 16 (HPV 16).

Blue Earth Diagnostics Ireland Ltd

Treatment of human papilloma virus (HPV) associated infections, precancers and cancers

phase 1 other active

1 trial
A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults.

GlaxoSmithKline

Respiratory Syncytial Virus Infections

phase 1 other active

1 trial
A study to assess the safety, and blood levels of CTX-187 after single and repeated intravenous doses in healthy volunteers and patients with bacterial infection

Centauri Biotech SL

Bacterial Infection

phase 1 other active

1 trial
A study to compare two different aramchol formulations in healthy volunteers.

Galmed Pharmaceuticals

Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Primary sclerosing cholangitis

phase 1 other active

1 trial
A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue (NA) treatment

GlaxoSmithKline

Hepatitis B, Chronic

phase 1 other active

1 trial
A study to learn about how itraconazole affects the level of emodepside in the blood when emodepside is given as a new type of tablet to healthy participants

Bayer AG

Soil-transmitted helminth infection, Onchocerciasis (river blindness)

phase 1 other active

1 trial
A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants

Bayer AG

Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

phase 1 other active

1 trial
A study to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis and coagulopathy

Bayer AG

Coagulopathy, Sepsis

phase 1 other active

1 trial
A study to test how well different doses of BI 3804379 are tolerated by healthy people and patients with MASH

Boehringer Ingelheim

Metabolic Dysfunction-associated Steatohepatitis

phase 1 other active

1 trial
AB-101

Arbutus Biopharma Corp

Chronic Hepatitis b

phase 1 small molecule completed

1 trial
AB-836

Arbutus Biopharma Corp

Chronic Hepatitis

phase 1 small molecule terminated

1 trial
ABI-4334

ASSEMBLY BIOSCIENCES, INC.

Chronic Hepatitis B

phase 1 small molecule completed

1 trial
ABI-4334 Tablet

ASSEMBLY BIOSCIENCES, INC.

Chronic Hepatitis B

phase 1 small molecule completed

1 trial
ABI-6250

ASSEMBLY BIOSCIENCES, INC.

Hepatitis Delta Virus

phase 1 small molecule completed

1 trial
ABI-H2158

ASSEMBLY BIOSCIENCES, INC.

Chronic Hepatitis B

phase 1 small molecule completed

3 trials
ABI-H2158 Reference Formulation

ASSEMBLY BIOSCIENCES, INC.

Chronic Hepatitis B

phase 1 small molecule completed

1 trial
ABI-H3733

ASSEMBLY BIOSCIENCES, INC.

Chronic Hepatitis B

phase 1 small molecule completed

1 trial
ABI-H3733 Liquid Oral Dosage Form

ASSEMBLY BIOSCIENCES, INC.

Chronic Hepatitis B

phase 1 small molecule completed

1 trial
ALG-000184

Aligos Therapeutics

Chronic Hepatitis B

phase 1 small molecule completed

1 trial
ALG-010133

Aligos Therapeutics

Chronic Hepatitis B

phase 1 small molecule terminated

1 trial
ALG-020572

Aligos Therapeutics

Chronic Hepatitis B

phase 1 small molecule terminated

1 trial

Frequently asked questions

How many infectious disease pipeline programs are tracked?

1,126 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Quick answer

Top sponsors

telaprevir

telaprevir or matching placebo

thalidomide

zelicapavir

zinc supplementation

(+)-SJ000557733

11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

480 mg Piperaquine phosphate

9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

A First-in-Human, randomised, double blind, placebo-controlled, single ascending dose trial to evaluate safety, tolerability, and pharmacokinetics of APC148 in healthy adults.

A Phase I study to evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects

A Randomized, Blinded, Placebo-Controlled Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects with Chronic Hepatitis B Virus Infection

A clinical study of MK-1289 in healthy adult men (MK-1289-001)

A clinical study of MK-3508 in healthy people (MK-3508-006)

A clinical study of MK-4646 in healthy people (MK-4646-002)

A clinical study of MK-4646 in people with HIV (MK-4646-003)

A clinical trial investigating the safety and biological activity of the antibody BNT351 in adults living without and with HIV

A first in human study of people with chronic hepatitis B, where all participants will receive the new drug PBGENE-HBV. This study will use increasing dose amounts of the drug to see how safe and bearable it is. The study will also test how well PBGENE-HBV works and how it is processed by the body.

A first-in-human trial to evaluate safety, tolerability, and pharmacokinetics of single and multiple oral doses of Debio 1453P in healthy adults

A phase 1 study of FluBHPVE6E7 immunotherapy in patients with HPV16-associated oropharyngeal squamous cell carcinoma

A randomized, single-blind, placebo-controlled, study to examine the safety, tolerability, and pharmacokinetics of M6229 administered as a 120-hour continuous infusion at two dose levels versus placebo in healthy subjects

A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg / 5 mL of clavulanic acid powder for oral suspension in healthy volunteers under fed conditions.

A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Taromentin® 500 mg + 125 mg film-coated tablets versus Augmentin® 500 mg + 125 mg film-coated tablets in healthy volunteers under fed conditions.

A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on two amoxicillin-clavulanic acid film-coated tablet formulations in healthy volunteers under fed conditions.

A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.

A study of different dose levels of FluBHPVE6E7 or placebo in women infected with the virus Human Papilloma Type 16 (HPV 16).

A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults.

A study to assess the safety, and blood levels of CTX-187 after single and repeated intravenous doses in healthy volunteers and patients with bacterial infection

A study to compare two different aramchol formulations in healthy volunteers.

A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue (NA) treatment

A study to learn about how itraconazole affects the level of emodepside in the blood when emodepside is given as a new type of tablet to healthy participants

A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants

A study to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis and coagulopathy

A study to test how well different doses of BI 3804379 are tolerated by healthy people and patients with MASH

AB-101

AB-836

ABI-4334

ABI-4334 Tablet

ABI-6250

ABI-H2158

ABI-H2158 Reference Formulation

ABI-H3733

ABI-H3733 Liquid Oral Dosage Form

ALG-000184

ALG-010133

ALG-020572

Frequently asked questions

Stay Ahead in Pharma